Loading...
XNAS
APVO
Market cap1mUSD
Jul 14, Last price  
2.95USD
1D
-1.67%
1Q
207.29%
Jan 2017
-91.36%
IPO
-92.73%
Name

Aptevo Therapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
33.87%
Rev. gr., 5y
-26.64%
Revenues
0k
170,00045,631,00033,601,00036,434,00014,658,00023,067,00032,424,0004,309,00012,292,0003,114,00000
Net income
-24m
L+38.59%
-53,337,000-51,115,000-59,317,000-112,415,0006,973,000-53,689,000-40,448,000-18,448,000-27,313,00042,669,000-17,411,000-24,130,000
CFO
-24m
L+102.77%
-51,392,000-47,007,000-48,760,000-36,862,000-41,573,000-51,422,000-42,383,000-29,318,000-21,679,000-21,022,000-11,730,000-23,785,000
Earnings
Aug 06, 2025

Profile

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
URL
http://aptevotherapeutics.com/
IPO date
Jul 20, 2016
Employees
45
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,114
-74.67%
Cost of revenue
24,602
29,445
32,656
Unusual Expense (Income)
NOPBT
(24,602)
(29,445)
(29,542)
NOPBT Margin
Operating Taxes
(35,655)
Tax Rate
NOPAT
(24,602)
(29,445)
6,113
Net income
(24,130)
38.59%
(17,411)
-140.80%
42,669
-256.22%
Dividends
Dividend yield
Proceeds from repurchase of equity
10,036
6,428
6,930
BB yield
-817.03%
-12,772.00%
-2,575.61%
Debt
Debt current
2,000
Long-term debt
9,258
10,794
13,614
Deferred revenue
Other long-term liabilities
Net debt
544
(6,110)
(7,021)
Cash flow
Cash from operating activities
(23,785)
(11,730)
(21,022)
CAPEX
(29)
Cash from investing activities
(29)
Cash from financing activities
15,595
5,998
(2,616)
FCF
(23,758)
(28,456)
3,311
Balance
Cash
8,714
16,904
22,635
Long term investments
Excess cash
8,714
16,904
22,479
Stockholders' equity
(247,493)
(223,386)
(205,988)
Invested Capital
256,877
241,004
233,497
ROIC
2.54%
ROCE
EV
Common stock shares outstanding
285
278
116
Price
4.31
2,281.22%
0.18
-92.20%
2.32
-70.52%
Market cap
1,228
2,340.65%
50
-81.29%
269
-67.91%
EV
1,772
(6,060)
(6,752)
EBITDA
(24,250)
(28,878)
(28,641)
EV/EBITDA
0.21
0.24
Interest
35,655
Interest/NOPBT